Show Summary Details
Page of

Acute Assessment of Mild Traumatic Brain Injury 

Acute Assessment of Mild Traumatic Brain Injury
Acute Assessment of Mild Traumatic Brain Injury

Linda Papa

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2016. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 18 January 2020

Most patients with mild TBI (mTBI) are discharged from the emergency department (ED) after a normal clinical examination and a reasonable period of observation and/or following a negative head computed tomography (CT) scan. Studies indicate that about 30% of mTBI patients discharged from the ED will have symptoms at 3 months and up to 15% will be symptomatic at 1 year post-injury. Serum markers have the potential to better manage patients with mTBI. Unlike clinical variables, serum biomarkers offer a more objective measure of injury and could complement clinical decision-making. In 2018, the US Food and Drug Administration approved the use of a blood test combining UCH-L1 and GFAP for detecting lesions on CT scan in adults with mTBI within 12 hours of injury. Introducing biomarkers into clinical practice requires well-designed studies with adequate sample sizes, proper sample timing, stringent reporting of outcome measures, and well-described assay performance characteristics.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.